Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat.com...